COMBINED VACCINE WITH WHOLE-CELL PERTUSSIS COMPONENT Russian patent published in 2017 - IPC A61K39/05 A61K39/10 A61K39/08 A61K39/95 A61K39/13 A61K39/29 

FIELD: medicine.

SUBSTANCE: group of inventions relates to medicine, specifically to immunology, and can be used for production of combined liquid vaccine. Fully liquid stable combined vaccine contains antigens of diphtheria (D), tetanus (T), whole cell pertussis (wP), IPV and Haemophilus influenzae (Hib). IPV antigens are Salk strains, selected from group of Mahoney strains type 1, MEF type 2 and Saukett type 3 or Sabin, selected from group Sabin 1 or 2. Antigen Hib is conjugated with protein selected from group comprising tetanus anatoxin, diphtheria anatoxin, CRM 197 and outer membrane protein of Neisseria meningitides. Wherein D is present in amount of about 1-40 Lf, T is present in amount of about 1-25 Lf, wP is present in amount of about 1–30 IOU per 0.5 ml and Hib b is present in amount of about 1–20 mcg per 0.5 ml. Group of inventions also relates to method of producing said vaccine and method for inducing immune response to any antigen, selected from group D, T, P, Hib, Hep or IPV, in individual. Application of this group of inventions enables to obtain fully liquid multicomponent vaccine with optimized dose of antigens, wherein in declared vaccine anatoxins of D, T are adsorbed on suitable adjuvant based on aluminium, while Hib component is not adsorbed on any of adjuvant, in vaccine 2-phenoxyethanol is used as preservative.

EFFECT: procedure for producing individual antigens is developed in vaccine composition with improved antigenicity, applicability and stability, which enables using component Hib b not in separate lyophilized form by formation of vaccine immediately before its introduction, but directly in liquid state of vaccine.

20 cl, 4 ex, 5 tbl